Search

Your search keyword '"Koschmieder, Steffen"' showing total 822 results
Start Over Author "Koschmieder, Steffen" Search Limiters Full Text
822 results on '"Koschmieder, Steffen"'

7. Proinflammatory phenotype of iPS cell-derived JAK2 V617F megakaryocytes induces fibrosis in 3D in vitro bone marrow niche

Author

Flosdorf, Niclas, Böhnke, Janik, de Toledo, Marcelo A.S., Lutterbach, Niklas, Lerma, Vanesa Gómez, Graßhoff, Martin, Olschok, Kathrin, Gupta, Siddharth, Tharmapalan, Vithurithra, Schmitz, Susanne, Götz, Katrin, Schüler, Herdit M., Maurer, Angela, Sontag, Stephanie, Küstermann, Caroline, Seré, Kristin, Wagner, Wolfgang, Costa, Ivan G., Brümmendorf, Tim H., Koschmieder, Steffen, Chatain, Nicolas, Castilho, Miguel, Schneider, Rebekka K., and Zenke, Martin

Published
2024
Full Text
View/download PDF

8. Non-canonical Hedgehog signaling mediates profibrotic hematopoiesis-stroma crosstalk in myeloproliferative neoplasms

Author

Pritchard, Jessica E., Pearce, Juliette E., Snoeren, Inge A.M., Fuchs, Stijn N.R., Götz, Katrin, Peisker, Fabian, Wagner, Silke, Benabid, Adam, Lutterbach, Niklas, Klöker, Vanessa, Nagai, James S., Hannani, Monica T., Galyga, Anna K., Sistemich, Ellen, Banjanin, Bella, Flosdorf, Niclas, Bindels, Eric, Olschok, Kathrin, Biaesch, Katharina, Chatain, Nicolas, Bhagwat, Neha, Dunbar, Andrew, Sarkis, Rita, Naveiras, Olaia, Berres, Marie-Luise, Koschmieder, Steffen, Levine, Ross L., Costa, Ivan G., Gleitz, Hélène F.E., Kramann, Rafael, and Schneider, Rebekka K.

Published
2024
Full Text
View/download PDF

10. Breakthrough infections in MPN-COVID vaccinated patients

Author

Barbui, Tiziano, Carobbio, Alessandra, Ghirardi, Arianna, Iurlo, Alessandra, De Stefano, Valerio, Sobas, Marta Anna, Rumi, Elisa, Elli, Elena Maria, Lunghi, Francesca, Gasior Kabat, Mercedes, Cuevas, Beatriz, Guglielmelli, Paola, Bonifacio, Massimiliano, Marchetti, Monia, Alvarez-Larran, Alberto, Fox, Laura, Bellini, Marta, Daffini, Rosa, Benevolo, Giulia, Carreno-Tarragona, Gonzalo, Patriarca, Andrea, Al-Ali, Haifa Kathrin, Andrade-Campos, Maria Marcio Miguel, Palandri, Francesca, Harrison, Claire, Foncillas, Maria Angeles, Osorio, Santiago, Koschmieder, Steffen, Magro Mazo, Elena, Kiladjian, Jean-Jacques, Bolaños Calderón, Estefanía, Heidel, Florian H., Quiroz Cervantes, Keina, Griesshammer, Martin, Garcia-Gutierrez, Valentin, Sanchez, Alberto Marin, Hernandez-Boluda, Juan Carlos, Lopez Abadia, Emma, Carli, Giuseppe, Sagues Serrano, Miguel, Kusec, Rajko, Xicoy Cirici, Blanca, Guenova, Margarita, Navas Elorza, Begona, Angona, Anna, Cichocka, Edyta, Kulikowska de Nałęcz, Anna, Cattaneo, Daniele, Bucelli, Cristina, Betti, Silvia, Borsani, Oscar, Cavalca, Fabrizio, Carbonell, Sara, Curto-Garcia, Natalia, Benajiba, Lina, Rambaldi, Alessandro, and Vannucchi, Alessandro Maria

Published
2022
Full Text
View/download PDF

11. Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms

Author

Mughal, Tariq I, Gotlib, Jason, Mesa, Ruben, Koschmieder, Steffen, Khoury, H Jean, Cortes, Jorge E, Barbui, Tiziano, Hehlmann, Rüdiger, Mauro, Michael, Saussele, Susanne, Radich, Jerald P, Van Etten, Richard A, Saglio, Giuseppe, Verstovek, Srdnan, Gale, Robert Peter, and Abdel-Wahab, Omar

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Rare Diseases, Hematology, Good Health and Well Being, Antineoplastic Agents, Calreticulin, Cardiovascular Diseases, Cell Transformation, Neoplastic, Chronic Disease, Congresses as Topic, Epigenesis, Genetic, Fusion Proteins, bcr-abl, Humans, Janus Kinase 2, Mastocytosis, Systemic, Mutation, Myeloproliferative Disorders, Protein Kinase Inhibitors, Remission Induction, Staurosporine, Translational Research, Biomedical, CML, MPN, TFR, Mastocytosis, CALR, Cardiotoxicity, JAK2 inhibitors, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

This review is based on the presentations and deliberations at the 7th John Goldman Chronic Myeloid Leukemia (CML) and Myeloproliferative Neoplasms (MPN) Colloquium which took place in Estoril, Portugal on the 15th October 2017, and the 11th post-ASH International Workshop on CML and MPN which took place on the 6th-7th December 2016, immediately after the 58th American Society of Hematology Annual Meeting. Rather than present a resume of the proceedings, we have elected to address some of the topical translational research and clinically relevant topics in greater detail. We address recent updates in the genetics and epigenetics of MPN, the mechanisms of transformation by mutant calreticulin, advances in the biology and therapy of systemic mastocytosis, clinical updates on JAK2 inhibitors and other therapeutic approaches for patients with MPNs, cardiovascular toxicity related to tyrosine kinase inhibitors and the concept of treatment-free remission for patients with CML.

Published
2018

15. Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms

Author

Mughal, Tariq I, Abdel-Wahab, Omar, Rampal, Raajit, Mesa, Ruben, Koschmieder, Steffen, Levine, Ross, Hehlmann, Rüdiger, Saglio, Giuseppe, Barbui, Tiziano, and Van Etten, Richard A

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Hematology, Cancer, Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Disease Models, Animal, Genetic Predisposition to Disease, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Mice, Molecular Targeted Therapy, Mutation, Myeloproliferative Disorders, Protein Kinase Inhibitors, Risk Assessment, Treatment Outcome, Molecular genetics, myeloid leukemias and dysplasias, stem and primitive progenitor cells, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

This review is based on the deliberations at the 5th John Goldman Colloquium held in Estoril on 2nd October 2015 and the 9th post-ASH International Workshop on chronic myeloid leukemia (CML) and BCR-ABL1-negative myeloproliferative neoplasms (MPN) which took place on the 10th-11th December 2014, immediately following the 56th American Society of Hematology Annual Meeting. It has been updated since and summarizes the most recent advances in the biology and therapy of these diseases, in particular updates of genetics of MPN, novel insights from mouse MPN models, targeting CML stem cells and its niche; clinical advances include updates on JAK2 inhibitors and other therapeutic approaches to BCR-ABL1-negative MPNs, the use of alpha interferons, updates on tyrosine kinase inhibitors (TKI) randomized trials in CML, TKI cessation studies, and optimal monitoring strategies.

Published
2016

17. The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling

Author

Olschok, Kathrin, primary, Altenburg, Bianca, additional, de Toledo, Marcelo A. S., additional, Maurer, Angela, additional, Abels, Anne, additional, Beier, Fabian, additional, Gezer, Deniz, additional, Isfort, Susanne, additional, Paeschke, Katrin, additional, Brümmendorf, Tim H., additional, Zenke, Martin, additional, Chatain, Nicolas, additional, and Koschmieder, Steffen, additional

Published
2023
Full Text
View/download PDF

18. JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms

Author

Rao, Tata Nageswara, Hansen, Nils, Hilfiker, Julian, Rai, Shivam, Majewska, Julia-Magdalena, Leković, Danijela, Gezer, Deniz, Andina, Nicola, Galli, Serena, Cassel, Teresa, Geier, Florian, Delezie, Julien, Nienhold, Ronny, Hao-Shen, Hui, Beisel, Christian, Di Palma, Serena, Dimeloe, Sarah, Trebicka, Jonel, Wolf, Dominik, Gassmann, Max, Fan, Teresa W.-M., Lane, Andrew N., Handschin, Christoph, Dirnhofer, Stefan, Kröger, Nicolaus, Hess, Christoph, Radimerski, Thomas, Koschmieder, Steffen, Čokić, Vladan P., and Skoda, Radek C.

Published
2019
Full Text
View/download PDF

19. P1004: ACTIVATING MUTATIONS IN JAK2 AND CALR DIFFERENTIALLY AFFECT INTRACELLULAR CALCIUM LEVELS AND CALCIUM FLUX

Author

Bhuria, Vikas, primary, Franz, Tobias, additional, Baldauf, Conny, additional, Böttcher, Martin, additional, Chatain, Nicolas, additional, Koschmieder, Steffen, additional, Brümmendorf, Tim H, additional, Mougiakakos, Dimitrios, additional, Schraven, Burkhart, additional, Kahlfuß, Sascha, additional, and Fischer, Thomas, additional

Published
2023
Full Text
View/download PDF

21. P1008: THE TELOMERASE INHIBITOR IMETELSTAT DIFFERENTIALLY TARGETS JAK2V617F- VERSUS CALR-MUTANT MYELOPROLIFERATIVE NEOPLASM CELLS AND INHIBITS JAK-STAT SIGNALING

Author

Olschok, Kathrin, primary, Altenburg, Bianca, additional, de Toledo, Marcelo A.S., additional, Maurer, Angela, additional, Abels, Anne, additional, Beier, Fabian, additional, Gezer, Deniz, additional, Isfort, Susanne, additional, Brümmendorf, Tim H, additional, Zenke, Martin, additional, Chatain, Nicolas, additional, and Koschmieder, Steffen, additional

Published
2023
Full Text
View/download PDF

23. Tyrosine kinase inhibitor–induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors

Author

Maifrede, Silvia, Nieborowska-Skorska, Margaret, Sullivan-Reed, Katherine, Dasgupta, Yashodhara, Podszywalow-Bartnicka, Paulina, Le, Bac Viet, Solecka, Martyna, Lian, Zhaorui, Belyaeva, Elizaveta A., Nersesyan, Alina, Machnicki, Marcin M., Toma, Monika, Chatain, Nicolas, Rydzanicz, Malgorzata, Zhao, Huaqing, Jelinek, Jaroslav, Piwocka, Katarzyna, Sliwinski, Tomasz, Stoklosa, Tomasz, Ploski, Rafal, Fischer, Thomas, Sykes, Stephen M., Koschmieder, Steffen, Bullinger, Lars, Valent, Peter, Wasik, Mariusz A., Huang, Jian, and Skorski, Tomasz

Published
2018
Full Text
View/download PDF

24. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19

Author

Barbui, Tiziano, De Stefano, Valerio, Alvarez-Larran, Alberto, Iurlo, Alessandra, Masciulli, Arianna, Carobbio, Alessandra, Ghirardi, Arianna, Ferrari, Alberto, Cancelli, Valeria, Elli, Elena Maria, Andrade-Campos, Marcio Miguel, Kabat, Mercedes Gasior, Kiladjian, Jean-Jaques, Palandri, Francesca, Benevolo, Giulia, Garcia-Gutierrez, Valentin, Fox, Maria Laura, Foncillas, Maria Angeles, Morcillo, Carmen Montoya, Rumi, Elisa, Osorio, Santiago, Papadopoulos, Petros, Bonifacio, Massimiliano, Cervantes, Keina Susana Quiroz, Serrano, Miguel Sagues, Carreno-Tarragona, Gonzalo, Sobas, Marta Anna, Lunghi, Francesca, Patriarca, Andrea, Elorza, Begoña Navas, Angona, Anna, Mazo, Elena Magro, Koschmieder, Steffen, Carli, Giuseppe, Cuevas, Beatriz, Hernandez-Boluda, Juan Carlos, Abadia, Emma Lopez, Cirici, Blanca Xicoy, Guglielmelli, Paola, Garrote, Marta, Cattaneo, Daniele, Daffini, Rosa, Cavalca, Fabrizio, Bellosillo, Beatriz, Benajiba, Lina, Curto-Garcia, Natalia, Bellini, Marta, Betti, Silvia, Harrison, Claire, Rambaldi, Alessandro, and Vannucchi, Alessandro Maria

Published
2021
Full Text
View/download PDF

26. JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation

Author

Czech, Julia, Cordua, Sabrina, Weinbergerova, Barbora, Baumeister, Julian, Crepcia, Assja, Han, Lijuan, Maié, Tiago, Costa, Ivan G., Denecke, Bernd, Maurer, Angela, Schubert, Claudia, Feldberg, Kristina, Gezer, Deniz, Brümmendorf, Tim H., Müller-Newen, Gerhard, Mayer, Jiri, Racil, Zdenek, Kubesova, Blanka, Knudsen, Trine, Sørensen, Anders L., Holmström, Morten, Kjær, Lasse, Skov, Vibe, Larsen, Thomas Stauffer, Hasselbalch, Hans C., Chatain, Nicolas, and Koschmieder, Steffen

Published
2019
Full Text
View/download PDF

27. Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms

Author

Nieborowska-Skorska, Margaret, Maifrede, Silvia, Dasgupta, Yashodhara, Sullivan, Katherine, Flis, Sylwia, Le, Bac Viet, Solecka, Martyna, Belyaeva, Elizaveta A., Kubovcakova, Lucia, Nawrocki, Morgan, Kirschner, Martin, Zhao, Huaqing, Prchal, Josef T., Piwocka, Katarzyna, Moliterno, Alison R., Wasik, Mariusz, Koschmieder, Steffen, Green, Tony R., Skoda, Radek C., and Skorski, Tomasz

Published
2017
Full Text
View/download PDF

28. Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group

Author

Koschmieder, Steffen, Isfort, Susanne, Jost, Philipp J., Parmentier, Stefani, Schaich, Markus, von Bubnoff, Nikolas, Stegelmann, Frank, Maurer, Angela, Crysandt, Martina, Gezer, Deniz, Kortmann, Maike, Franklin, Jeremy, Wolf, Dominik, Frank, Julia, Hellmich, Martin, Brümmendorf, Tim Henrik, German Study Group for Myeloproliferative Neoplasms (GSG-MPN), Heidel, Florian H., Hochhaus, Andreas, Schafhausen, Philippe, Griesshammer, Martin, Wolleschak, Denise, Platzbecker, Uwe, and Döhner, Konstanze

Subjects
ddc:610, Hematology, General Medicine
Abstract

Annals of hematology 102(2), 349-358 (2022). doi:10.1007/s00277-022-05080-7, Published by Springer, Berlin ; Heidelberg ; New York

Published
2022

29. The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues

Author

Van Etten, Richard A., Koschmieder, Steffen, Delhommeau, Francois, Perrotti, Danilo, Holyoake, Tessa, Pardanani, Animesh, Mesa, Ruben, Green, Tony, Ibrahim, Amr R., Mughal, Tariq, Gale, Robert Peter, and Goldman, John

Subjects
myeloproliferative neoplasm, JAK2, Ph-negative, Ph-positive
Abstract

This review focuses on topical issues in the biology and treatment of the myeloproliferative neoplasms (MPNs). Studies in transgenic mice suggest that BCR-ABL1 reduces the fraction of self-renewing ‘leukemic’ stem cells in the bone marrow but that some of these cells survive treatment with imatinib. This also seems to operate in humans. Data from models also strongly support the notion that JAK2V617F can initiate and sustain MPNs in mice; relevance to disease in humans is less clear. These data also support the hypothesis that level of JAK2V617F expression influences the MPN phenotype: higher levels favor erythrocytosis whereas lower levels favor thrombocytosis. Although TET2-mutations were thought to precede JAK2V617F in some persons with MPNs, it now appears that TET2 mutations may occur after JAK2V617F. Further understanding of signal-transduction pathways activated in chronic myeloid leukemia suggests various possible targets for new therapies including the WNT/beta catenin, notch and hedgehog pathways. Finally, the clinical role of the new JAK2- and BCR-ABL1-inhibitors is considered. Much further progress is likely in several of these areas soon.

Published
2011

30. Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET

Author

Wille, Kai, primary, Brouka, Maja, additional, Bernhardt, Johannes, additional, Rüfer, Axel, additional, Niculescu-Mizil, Emilia, additional, Gotic, Mirjana, additional, Isfort, Susanne, additional, Koschmieder, Steffen, additional, Barbui, Tiziano, additional, Sadjadian, Parvis, additional, Becker, Tatjana, additional, Kolatzki, Vera, additional, Meixner, Raphael, additional, Marchi, Hannah, additional, Fuchs, Christiane, additional, Stegelmann, Frank, additional, Döhner, Konstanze, additional, Kiladjian, Jean-Jacques, additional, and Griesshammer, Martin, additional

Published
2023
Full Text
View/download PDF

31. Identification of Adult Patients With Classical Dyskeratosis Congenita or Cryptic Telomere Biology Disorder by Telomere Length Screening Using Age-modified Criteria

Author

Tometten, Mareike, primary, Kirschner, Martin, additional, Meyer, Robert, additional, Begemann, Matthias, additional, Halfmeyer, Insa, additional, Vieri, Margherita, additional, Kricheldorf, Kim, additional, Maurer, Angela, additional, Platzbecker, Uwe, additional, Radsak, Markus, additional, Schafhausen, Philippe, additional, Corbacioglu, Selim, additional, Höchsmann, Britta, additional, Matthias Wilk, C., additional, Hinze, Claas, additional, Chromik, Jörg, additional, Heuser, Michael, additional, Kreuter, Michael, additional, Koschmieder, Steffen, additional, Panse, Jens, additional, Isfort, Susanne, additional, Kurth, Ingo, additional, Brümmendorf, Tim H., additional, and Beier, Fabian, additional

Published
2023
Full Text
View/download PDF

32. Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms.

Author

Bermes, Max, Rodriguez, Maria Jimena, de Toledo, Marcelo Augusto Szymanski, Ernst, Sabrina, Müller-Newen, Gerhard, Brümmendorf, Tim Henrik, Chatain, Nicolas, Koschmieder, Steffen, and Baumeister, Julian

Subjects
MYELOPROLIFERATIVE neoplasms, BRCA genes, DNA repair, HOMOLOGOUS recombination, DOUBLE-strand DNA breaks, POLY(ADP-ribose) polymerase, VENOM, TYPE I interferons
Abstract

Myeloproliferative neoplasms (MPN) are rare hematologic disorders characterized by clonal hematopoiesis. Familial clustering is observed in a subset of cases, with a notable proportion exhibiting heterozygous germline mutations in DNA double-strand break repair genes (e.g., BRCA1). We investigated the therapeutic potential of targeting BRCA1 haploinsufficiency alongside the JAK2V617F driver mutation. We assessed the efficacy of combining the PARP inhibitor olaparib with interferon-alpha (IFNα) in CRISPR/Cas9-engineered Brca1+/− Jak2V617F-positive 32D cells. Olaparib treatment induced a higher number of DNA double-strand breaks, as demonstrated by γH2AX analysis through Western blot (p = 0.024), flow cytometry (p = 0.013), and confocal microscopy (p = 0.071). RAD51 foci formation was impaired in Brca1+/− cells compared to Brca1+/+ cells, indicating impaired homologous recombination repair due to Brca1 haploinsufficiency. Importantly, olaparib enhanced apoptosis while diminishing cell proliferation and viability in Brca1+/− cells compared to Brca1+/+ cells. These effects were further potentiated by IFNα. Olaparib induced interferon-stimulated genes and increased endogenous production of IFNα in Brca1+/− cells. These responses were abrogated by STING inhibition. In conclusion, our findings suggest that the combination of olaparib and IFNα presents a promising therapeutic strategy for MPN patients by exploiting the synthetic lethality between germline BRCA1 mutations and the JAK2V617F MPN driver mutation. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

34. Recurrent somatic mutations are rare in patients with cryptic dyskeratosis congenita

Author

Kirschner, Martin, Maurer, Angela, Wlodarski, Marcin W., Ventura Ferreira, Monica S., Bouillon, Anne-Sophie, Halfmeyer, Insa, Blau, Wolfgang, Kreuter, Michael, Rosewich, Martin, Corbacioglu, Selim, Beck, Joachim, Schwarz, Michaela, Bittenbring, Jörg, Radsak, Markus P., Wilk, Christian Matthias, Koschmieder, Steffen, Begemann, Matthias, Kurth, Ingo, Schemionek, Mirle, Brümmendorf, Tim H., and Beier, Fabian

Published
2018
Full Text
View/download PDF

35. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet

Author

Barbui, Tiziano, Tefferi, Ayalew, Vannucchi, Alessandro M., Passamonti, Francesco, Silver, Richard T., Hoffman, Ronald, Verstovsek, Srdan, Mesa, Ruben, Kiladjian, Jean-Jacques, Hehlmann, Rȕdiger, Reiter, Andreas, Cervantes, Francisco, Harrison, Claire, Mc Mullin, Mary Frances, Hasselbalch, Hans Carl, Koschmieder, Steffen, Marchetti, Monia, Bacigalupo, Andrea, Finazzi, Guido, Kroeger, Nicolaus, Griesshammer, Martin, Birgegard, Gunnar, and Barosi, Giovanni

Published
2018
Full Text
View/download PDF

36. KIT D816V Mast Cells Derived from Induced Pluripotent Stem Cells Recapitulate Systemic Mastocytosis Transcriptional Profile

Author

de Toledo, Marcelo A. S., primary, Fu, Xuhuang, additional, Maié, Tiago, additional, Buhl, Eva M., additional, Götz, Katrin, additional, Schmitz, Susanne, additional, Kaiser, Anne, additional, Boor, Peter, additional, Braunschweig, Till, additional, Chatain, Nicolas, additional, Costa, Ivan G., additional, Brümmendorf, Tim H., additional, Koschmieder, Steffen, additional, and Zenke, Martin, additional

Published
2023
Full Text
View/download PDF

41. BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis

Author

Verstovsek, Srdan, primary, Al-Ali, Haifa Kathrin, additional, Mascarenhas, John, additional, Perkins, Andrew, additional, Vannucchi, Alessandro Maria, additional, Mohan, Sanjay R, additional, Scott, Bart L, additional, Woszczyk, Dariusz, additional, Koschmieder, Steffen, additional, García-Delgado, Regina, additional, László, Rejtő, additional, McGreivy, Jesse S, additional, Rothbaum, Wayne P, additional, and Kiladjian, Jean-Jacques, additional

Published
2022
Full Text
View/download PDF

42. Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

Author

Koschmieder, Steffen, primary, Isfort, Susanne, additional, Heidel, Florian H., additional, Hochhaus, Andreas, additional, Becker, Heiko, additional, Jost, Philipp J., additional, Schafhausen, Philippe, additional, Griesshammer, Martin, additional, Wolleschak, Denise, additional, Haenel, Mathias, additional, Göthert, Joachim R, additional, Teichmann, Lino L., additional, Sockel, Katja, additional, Radsak, Markus P., additional, Reiter, Andreas, additional, Döhner, Konstanze, additional, Balleisen, Sebastian, additional, Jaekel, Nadja, additional, von Bubnoff, Nikolas, additional, Stegelmann, Frank, additional, Gezer, Deniz, additional, Kortmann, Maike, additional, Frank, Julia, additional, Hellmich, Martin, additional, and Brümmendorf, Tim H., additional

Published
2022
Full Text
View/download PDF

43. Non-Canonical Gli1 Activation Mediates Profibrotic Hematopoiesis-Stroma Crosstalk in MPN

Author

Pritchard, Jessica E., primary, Pearce, Juliette, additional, Snoeren, Inge, additional, Fuchs, Stijn, additional, Götz, Katrin, additional, Wagner, Silke, additional, Olschok, Kathrin, additional, Chatain, Nicolas, additional, Koschmieder, Steffen, additional, Berres, Marie-Luise, additional, Costa, Ivan, additional, Gleitz, Helene, additional, Kramann, Rafael, additional, and Schneider, Rebekka K., additional

Published
2022
Full Text
View/download PDF

44. Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)

Author

Barbui, Tiziano, primary, Carobbio, Alessandra, additional, Ghirardi, Arianna, additional, Iurlo, Alessandra, additional, De Stefano, Valerio, additional, Sobas, Marta Anna, additional, Rumi, Elisa, additional, Elli, Elena Maria, additional, Lunghi, Francesca, additional, Gasior Kabat, Mercedes, additional, Cuevas, Beatriz, additional, Guglielmelli, Paola, additional, Bonifacio, Massimiliano, additional, Marchetti, Monia, additional, Alvarez-Larran, Alberto, additional, Fox, Laura Maria, additional, Bellini, Marta, additional, Daffini, Rosa, additional, Benevolo, Giulia, additional, Carreño, Gonzalo, additional, Patriarca, Andrea, additional, Al-Ali, Haifa Kathrin, additional, Andrade, Marcio, additional, Palandri, Francesca, additional, Harrison, Claire, additional, Foncillas, Maria Angeles, additional, Osorio, Santiago, additional, Koschmieder, Steffen, additional, Magro, Elena, additional, Kiladjian, Jean-Jacques, additional, Bolaños, Estefanía, additional, Heidel, Florian H., additional, Quiroz, Keina, additional, Griesshammer, Martin, additional, García Gutiérrez, Valentín, additional, Marin Sanchez, Alberto, additional, Hernandez Boluda, Juan Carlos, additional, Lopez Abadia, Emma, additional, Carli, Giuseppe, additional, Sagüés, Miguel, additional, Kusec, Rajko, additional, Xicoy, Blanca, additional, Guenova, Margarita, additional, Navas, Begoña, additional, Angona, Anna, additional, Cichocka, Edyta, additional, Masternak, Anna, additional, Cattaneo, Daniele, additional, Bucelli, Cristina, additional, Betti, Silvia, additional, Borsani, Oscar, additional, Cavalca, Fabrizio, additional, Carbonell, Sara, additional, Curto-Garcia, Natalia, additional, Benajiba, Lina, additional, Rambaldi, Alessandro, additional, and Vannucchi, Alessandro M., additional

Published
2022
Full Text
View/download PDF

45. Clinicohematologic and Molecular Response of Essential Thrombocythemia Patients Treated with Pegylated Interferon-Alpha: A Multicenter Study on Behalf of the German Study Group-MPN (GSG-MPN)

Author

Stegelmann, Frank, primary, Teichmann, Lino L., additional, Heidel, Florian H., additional, Crodel, Carl C., additional, Ernst, Thomas, additional, Kreil, Sebastian, additional, Reiter, Andreas, additional, Otten, Sara, additional, Schauer, Stefanie, additional, Körber, Ruth-Miriam, additional, Kricheldorf, Kim, additional, Isfort, Susanne, additional, Döhner, Hartmut, additional, Brümmendorf, Tim H., additional, Griesshammer, Martin, additional, Döhner, Konstanze, additional, and Koschmieder, Steffen, additional

Published
2022
Full Text
View/download PDF

47. A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses

Author

Pettit, Kristen M., primary, Gill, Harinder, additional, Yacoub, Abdulraheem, additional, Bradley, Terrence, additional, Gerds, Aaron T., additional, Tatarczuch, Maciej, additional, Shortt, Jake, additional, Curtin, Natasha Joan, additional, Rossetti, James M., additional, Burbury, Kate, additional, Mead, Adam J, additional, Göthert, Joachim R, additional, Koschmieder, Steffen, additional, Reyer, Matt, additional, Siranosian, Benjamin, additional, Natsoulis, Georges, additional, Stevenson, William S, additional, Ewing, Joanne, additional, Chacko, Joseph M., additional, Rumi, Elisa, additional, Halpern, Anna B., additional, Palandri, Francesca, additional, Vianelli, Nicola, additional, Passamonti, Francesco, additional, Mesa, Ruben, additional, Marchetti, Monia, additional, Harrison, Claire, additional, Vannucchi, Alessandro M., additional, Watts, Justin, additional, Ross, David M, additional, Talpaz, Moshe, additional, and Rienhoff, Hugh Young, additional

Published
2022
Full Text
View/download PDF

48. Verify: A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera

Author

Verstovsek, Srdan, primary, Kuykendall, Andrew, additional, Hoffman, Ronald, additional, Koschmieder, Steffen, additional, Passamonti, Francesco, additional, Valone, Frank, additional, Modi, Nishit B., additional, Khanna, Sarita, additional, O'Connor, Paula G., additional, Gupta, Suneel K., additional, and Kiladjian, Jean-Jacques, additional

Published
2022
Full Text
View/download PDF

49. MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor

Author

Mascarenhas, John, primary, Harrison, Claire, additional, Kiladjian, Jean-Jacques, additional, Komrokji, Rami S., additional, Koschmieder, Steffen, additional, Vannucchi, Alessandro M., additional, Berry, Tymara, additional, Redding, Denise, additional, Sherman, Laurie, additional, Dougherty, Souria, additional, Peng, Lixian, additional, Sun, Libo, additional, Huang, Fei, additional, Wan, Ying, additional, Feller, Faye, additional, and Verstovsek, Srdan, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results